COOCooper Companies, Inc.

Upcoming Earnings

We were not able to find an announced earnings date for this symbol yet. Check back again later

Company Info

CEO

Albert G. White

Location

California, USA

Exchange

Nasdaq

Website

https://coopercos.com

Summary

CooperVision and CooperSurgical segments provide medical devices, fertility, genomics, diagnostics, and contraception to health care professionals and patients.

Company Info

CEO

Albert G. White

Location

California, USA

Exchange

Nasdaq

Website

https://coopercos.com

Summary

CooperVision and CooperSurgical segments provide medical devices, fertility, genomics, diagnostics, and contraception to health care professionals and patients.

AI Insights for COO
4 min read

Quick Summary

The Cooper Companies, Inc. is a medical device company operating mainly through CooperVision and CooperSurgical. CooperVision sells contact lenses used to correct common vision issues such as nearsightedness, farsightedness, astigmatism, presbyopia, myopia, ocular dryness, and eye fatigue. CooperSurgical provides products and services for fertility, genomics, diagnostics, contraception, and women’s health procedures. The company’s main customers include eye care professionals, hospitals, fertility clinics, obstetric and gynecology practices, surgical centers, and patients who rely on recurring medical products. The business benefits from recurring demand because contact lenses and many clinical consumables are purchased repeatedly rather than as one-time durable equipment.

Strengths

•

Cooper’s primary strength is its position in specialized medical device markets with recurring demand characteristics.

•

Contact lenses are frequently replaced, which can create repeat revenue and durable customer relationships with eye care professionals.

•

The company also has a diversified platform through CooperSurgical, giving it exposure to fertility, genomics, diagnostics, contraception, and women’s health.

•

Its gross profit level suggests that the business has meaningful product value and pricing power in selected categories.

•

Cooper also benefits from established brands, global distribution, clinical relationships, and a portfolio that addresses long-term health care needs.

Key Risks

•

Cooper faces risks from macroeconomic weakness, because patients may defer certain elective or out-of-pocket health care spending.

•

Currency fluctuations can hurt reported revenue and earnings when international sales are translated into U.S. dollars.

•

Regulatory requirements and product quality issues are also important risks because medical device companies must meet strict safety and compliance standards.

•

Competition could pressure prices or reduce market share if rivals launch superior products or increase promotions.

What to Watch

The most recent data identifies the company as reporting for fiscal year 2026, quarter Q4, with operating revenue of about $1.066 billion and total gross profit of about $711.9 million.
Total operating income was about $222 million, while net income was about $432.8 million, indicating that profitability remains a central focus for investors.
The provided news flow emphasizes continuing demand for CooperVision and CooperSurgical products, especially contact lenses, fertility products, and surgical offerings.
It also highlights that acquisitions have been an important part of the company’s growth strategy.
No specific new product launch or partnership is listed in the provided quarter data, so the key quarter events appear to center on financial performance, product demand, and margin considerations.

Price Drivers

•

COO’s stock price is driven heavily by revenue growth, earnings performance, margins, and investor confidence in the CooperVision and CooperSurgical segments.

•

The company’s valuation metrics show a price-to-earnings ratio of about 20.03, an earnings yield of about 4.99%, and an EV-to-EBITDA multiple of about 14.63, so changes in growth expectations can meaningfully affect the share price.

•

Demand for silicone hydrogel lenses, toric lenses, multifocal lenses, fertility products, and surgical consumables can support revenue momentum.

•

However, currency headwinds, higher costs, and margin pressure can weigh on earnings and investor sentiment.

•

The stock may also react to quarterly results, guidance changes, acquisition activity, health care spending trends, and broader market appetite for medical technology stocks.

Recent News

•

Recent company-related news indicates that Cooper Companies is viewed as positioned for growth through demand in CooperVision and CooperSurgical.

•

The news specifically mentions acquisitions, silicone hydrogel lenses, fertility products, and surgical products as growth contributors.

•

It also notes that fiscal 2024 revenue and EPS were expected to grow, although currency headwinds, higher costs, margin pressure, and weak share performance weighed on the outlook.

•

Zacks rated COO as Hold in the cited coverage, suggesting a balanced view rather than a strongly bullish recommendation.

•

Several other provided news items use the term COO to mean chief operating officer and are not directly related to Cooper Companies, so they should not be treated as company-specific catalysts.

Market Trends

•

Broader market trends affecting Cooper include aging populations, rising vision correction needs, and growing demand for premium contact lenses.

•

Increased screen usage and lifestyle changes may support demand for products that address eye fatigue, dryness, and changing vision needs.

•

Fertility and reproductive health markets may benefit from delayed family formation, greater use of assisted reproductive technologies, and expanding awareness of reproductive care options.

•

At the same time, health care systems and consumers remain sensitive to cost, reimbursement, inflation, and economic uncertainty.

•

Medical device companies are also affected by regulatory scrutiny, supply chain reliability, currency movements, and investor preference for profitable growth.

AI-generated summary for educational purposes only. Not investment advice. Always do your own research before investing.

Community Research

Research from investors like you

Be the first to share your analysis on COO

Help fellow investors make informed decisions by sharing your research on fundamentals, catalysts, and outlook.

Topics: Company overview • Products • Competitors • Strengths & Risks

Symbol's posts

avatar
@EmmaStone 5 months ago

$COO Delivers Another Solid Quarter

$COO Delivers Another Solid Quarter

Cooper Companies ($COO) reported Q2 results that highlighted continued strength across its healthcare and medical device businesses. Demand for contact lenses and women's health products remained a key growth driver, helping the company maintain momentum in a resilient healthcare market. Investors are also watching margins, cost management, and future guidance as Cooper looks to build on its steady long-term growth story. With healthcare demand staying strong, continues to be one of the names benefiting from defensive growth trends.

avatar
@UndyingValue 11 months ago

Market recap: November ends choppy, upcoming Fed meeting, and 2026 targets

Market recap: November ends choppy, upcoming Fed meeting, and 2026 targets

post thumbnail

No more topics to show